Eli Lilly

Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
Pharma Voice
Fri, 06/28/24 - 11:17 am
Big Pharma
Neuroscience
Prothena Biosciences
Biogen
Eisai
Pfizer
AbbVie
Eli Lilly
Bristol Myers Squibb
Where the future of Alzheimer's drugs is heading
Axios
Fri, 06/28/24 - 11:15 am
Alzheimer's disease
drug development
Eli Lilly
House panel proposes new strategy for Medicare to cover weight loss drugs Wegovy, Zepbound
Stat
Thu, 06/27/24 - 11:13 am
Novo Nordisk
Medicare
Wegovy
Zepbound
Eli Lilly
legislation
Eli Lilly inks OpenAI deal for discovering new antibiotics
Fierce Biotech
Tue, 06/25/24 - 11:28 am
Eli Lilly
OpenAI
antimicrobial resistance
antibiotics
5 FDA Decisions to Watch in the Second Half of 2024
BioSpace
Mon, 06/24/24 - 11:29 am
FDA
Eli Lilly
donanemab
Alzheimer's disease
Adaptimmune
afami-cel
advanced synovial sarcoma
Lykos Therapeutics
MDMA
PTSD
Bristol Myers Squibb
KarXT
schizophrenia
Daiichi Sankyo
AstraZeneca
Dato-DXd
non-small cell lung cancer
Lilly Sees Path for Zepbound’s Label Expansion With Phase III Sleep Apnea Win
BioSpace
Mon, 06/24/24 - 11:20 am
Eli Lilly
Zepbound
clinical trials
sleep apnea
What Would a Donanemab Approval Mean for Leqembi?
BioSpace
Mon, 06/24/24 - 10:47 am
Eli Lilly
donanemab
Biogen
Eisai
Leqembi
FDA
Alzheimer's disease
Lilly files more lawsuits to curb sales of counterfeit Mounjaro
Reuters
Thu, 06/20/24 - 11:26 am
Eli Lilly
drug counterfeiting
Mounjaro
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
Motley Fool
Sun, 06/16/24 - 08:54 pm
Eli Lilly
Alzheimer's disease
donanemab
GLP-1 global obesity market to reach $111B by 2033, despite headwinds: GlobalData
BioSpace
Fri, 06/14/24 - 11:48 am
GLP-1 agonists
Novo Nordisk
Eli Lilly
obesity
weight loss
Employer coverage for weight-loss drugs rises sharply, survey finds
Reuters
Thu, 06/13/24 - 11:05 pm
insurance
weight loss
obesity
Eli Lilly
Novo Nordisk
Wegovy
Zepbound
Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
Pharma Voice
Thu, 06/13/24 - 10:50 am
Eli Lilly
Alzheimer's disease
donanemab
amyloid
tau
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
BioPharma Dive
Mon, 06/10/24 - 06:09 pm
Eli Lilly
FDA
donanemab
Alzheimer's disease
Eli Lilly exec says seeing out of pocket payments for obesity drug in US
Reuters
Mon, 06/10/24 - 06:06 pm
Eli Lilly
Zepbound
Mounjaro
patients
obesity
diabetes
Added health benefits of Wegovy, Zepbound could attract more men, doctors say
Reuters
Mon, 06/10/24 - 11:15 am
Novo Nordisk
Wegovy
Eli Lilly
Zepbound
men's health
sleep apnea
heart disease
Boehringer, Lilly face off in MASH at EASL
Pharmaphorum
Mon, 06/10/24 - 11:14 am
Eli Lilly
Boehringer Ingelheim
MASH
EASL
tirzepatide
survodutide
FDA staff raise no major concerns about Eli Lilly Alzheimer's drug
Reuters
Thu, 06/6/24 - 09:11 pm
Eli Lilly
FDA
Alzheimer's disease
donanemab
FDA lays out donanemab concerns ahead of meeting, as Lilly vigorously defends safety
Fierce Biotech
Thu, 06/6/24 - 11:45 am
Eli Lilly
donanemab
FDA
Alzheimer's disease
Top ten biopharma R&D deals of 2024
Nature
Wed, 06/5/24 - 11:24 am
R&D
Novartis
Argo Biopharmaceutical
Roche
MOMA Therapeutics
Boehringer Ingelheim
Suzhou Ribo Life Science
Eli Lilly
Isomorphic Labs
Merus
Gilead Sciences
Novo Nordisk
Neomorph
AbbVie
Umoja Biopharma
Merck KGaA
Caris Life Sciences
Voyager Therapeutics
Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expansion
BioSpace
Wed, 06/5/24 - 11:08 am
Eli Lilly
NASH
MASH
clinical trials
tirzepatide

Pages